Protara Q4 net loss $39.0M; cash $102.3M; TARA-002 data expected Q2 2023

Protara Therapeutics, Inc.

Net loss Q4 2022: $39.0M ($3.46 per share) vs $10.2M ($0.91) in Q4 2021; includes $29.5M goodwill impairment.
Full year 2022 net loss $66.0M ($5.86 per share) vs $47.3M ($4.21) in 2021; R&D expense $16.8M, G&A $20.7M.
Cash, equivalents, and marketable debt securities $102.3M as of Dec 31, 2022; expected to fund operations into 2025.
Phase 1a data from ADVANCED-1 trial of TARA-002 in NMIBC expected in Q2 2023; Phase 2 trial in LMs to start 2H 2023.
Prospective study of IV Choline Chloride in IFALD ongoing; results expected Q3 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.5

Protara Therapeutics, Inc. reported the quarter and year ended December 31, 2022 results: net income net loss of $39.0 million, or $3.46 per share.

Period: the quarter and year ended December 31, 2022
Net income: net loss of $39.0 million, or $3.46 per share
Result: reported results

Exact text from the filing

On March 8, 2023, Protara Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

View on SEC.gov

Browse all earnings releases →

Protara Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-018371

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.